Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
about
Drug development in Alzheimer's disease: the path to 2025Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In SilicoEffect of LXR/RXR agonism on brain and CSF Aβ40 levels in ratsExploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers.Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical EvidenceEssential Dietary Bioactive Lipids in Neuroinflammatory Diseases.Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models.Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease.Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.Preclinical PET Neuroimaging of [11C]Bexarotene.A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjectsRemyelinating Pharmacotherapies in Multiple Sclerosis.Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.Binding of Bexarotene to the Amyloid Precursor Protein Transmembrane Domain in Liposomes Alters its α-Helical Conformation but Inhibits γ-Secretase Non-Selectively.
P2860
Q27007748-7C2A4029-7E1A-4D9D-8C0C-373701354DB3Q28551351-05D75F2B-5B22-4B78-937E-394824A80C70Q28602802-B0C4BE03-BB18-4E3E-888C-83D9D5AAD1BFQ30239964-E1C92600-AAEC-48B7-81EE-198514E126AAQ36774123-09AD665E-4261-43DF-9E82-8FA8815AB537Q37644290-0C73D694-FFE9-479D-92B5-A93CD3D85607Q38407177-AF183AC5-0291-4261-9383-74EA5CA45617Q38715276-C64BB955-A2F0-4C04-B7D6-3933D5970037Q38891157-29949D00-0C20-4094-9192-CFE0CDF55072Q39005365-642D4395-C328-4E40-909A-AA355BD08EF7Q39164346-FA91BE82-6EC4-47EC-AF71-5E88BBEAAB9AQ39689655-6F58025B-30E1-435F-944E-8218DFDFCE65Q41015702-5192CA37-D694-4276-8BAA-88F45D64B23BQ42689665-19649C27-C801-4776-BE0D-49358990D377Q46682011-52427501-C4E0-4DF5-AC76-A3EBA6ECF438Q47677964-5F9DC140-3DFF-413A-9ABF-827FFA516348Q49962878-393313D4-AEE3-4714-922B-9A980FCDF22EQ52714855-8E0AD3D8-05DA-442A-BB1D-430E7754E808
P2860
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Double-blind, placebo-controll ...... moderate Alzheimer's disease.
@ast
Double-blind, placebo-controll ...... moderate Alzheimer's disease.
@en
type
label
Double-blind, placebo-controll ...... moderate Alzheimer's disease.
@ast
Double-blind, placebo-controll ...... moderate Alzheimer's disease.
@en
prefLabel
Double-blind, placebo-controll ...... moderate Alzheimer's disease.
@ast
Double-blind, placebo-controll ...... moderate Alzheimer's disease.
@en
P2093
P2860
P1476
Double-blind, placebo-controll ...... moderate Alzheimer's disease.
@en
P2093
Abhinay Joshi
Chelcie Heaney
James Bena
Jefferson W Kinney
Joanne Moll-Tudla
Kate Zhong
Michael Devous
Michael Pontecorvo
P2860
P2888
P356
10.1186/S13195-016-0173-2
P407
P577
2016-01-29T00:00:00Z
P5875
P6179
1039647768